Ablynx And Merck Serono Launch Their Fourth Nanobody R&D Alliance
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian drug-discovery company Ablynx and Germany’s Merck Serono have expanded their ties by creating a research alliance that may lead to the development of at least four Nanobody agents to treat disease.